Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


McClellan back at FDA

This article was originally published in The Tan Sheet

Executive Summary

Brookings Institution's Engelberg Center for Healthcare Reform Director Mark McClellan returns to his FDA bailiwick as chairman of the Reagan-Udall Foundation. The former FDA commissioner will lead the private organization established by the FDA Amendments Act to advance the agency's Critical Path initiative and identify unmet scientific needs. Other Reagan-Udall board members announced Nov. 16 include representatives from Genzyme and Johnson & Johnson. House Agriculture-FDA Appropriations Chairwoman Rosa DeLauro, D-Conn., has requested FDA stop activities related to the creation of the foundation until the agency addresses issues of industry influence (1"The Tan Sheet" Nov. 12, 2007, In Brief)...

Related Content

Reagan-Udall pushback





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts